for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Stratec SE

SBSG.DE

Latest Trade

65.10EUR

Change

-1.00(-1.51%)

Volume

2,309

Today's Range

64.90

 - 

66.40

52 Week Range

52.30

 - 

77.60

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
66.10
Open
66.10
Volume
2,309
3M AVG Volume
0.13
Today's High
66.40
Today's Low
64.90
52 Week High
77.60
52 Week Low
52.30
Shares Out (MIL)
12.03
Market Cap (MIL)
783.17
Forward P/E
--
Dividend (Yield %)
--

Next Event

Stratec SE at Bankhaus Lampe Deutschland Conference

Latest Developments

More

STRATEC 9-Month Adjusted EBIT Up At EUR 20.1 Mln, Up 17.8%

Stratec H1 Adjusted Consolidated Net Income Up At 10.3 Million Euros

STRATEC Q1 Adj EBIT Up 26.2% At EUR 5.1 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Stratec SE

Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.

Contact Info

Gewerbestr. 37

+49.7082.79160

https://www.stratec.com/

Executive Leadership

Frank Hiller

Independent Chairman of the Supervisory Board

Marcus Wolfinger

Chairman of the Management Board, Chief Executive Officer

Rainer Baule

Independent Deputy Chairman of the Supervisory Board

Robert Siegle

Director of Finance and Human Resources, Member of the Board of Management

Claus Vielsack

Member of the Management Board, Director of Product Development

Key Stats

2.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.2K

2017

0.2K

2018

0.2K

2019(E)

0.2K
EPS (EUR)

2016

2.130

2017

2.330

2018

0.920

2019(E)

2.112
Price To Earnings (TTM)
57.91
Price To Sales (TTM)
3.66
Price To Book (MRQ)
5.18
Price To Cash Flow (TTM)
23.03
Total Debt To Equity (MRQ)
67.82
LT Debt To Equity (MRQ)
59.01
Return on Investment (TTM)
5.64
Return on Equity (TTM)
4.76

Latest News

Latest News

BRIEF-STRATEC Biomedical To Propose Increased Dividend Of EUR 0.80/Shr

* DIVIDEND 0.80 EURPER SHARE VERSUS 0.77 EURPER SHARE YEAR AGO

BRIEF-STRATEC Biomedical To Modify Its Legal Form To That Of European Company

* INTENDS TO MODIFY ITS LEGAL FORM TO THAT OF A EUROPEAN COMPANY

BRIEF-Stratec Biomedical 9mth adj EBIT up at EUR 24.0 mln

* ADJUSTED EBIT MARGIN OF 15.9% IN 9M|2017 (9M|2016: 14.6%)

BRIEF-STRATEC Biomedical H1 net profit down 3.5 percent at 9.9 mln euros

* NOT ISSUING ANY SPECIFIC STATEMENT CONCERNING ITS EXPECTATIONS FOR 2018

BRIEF-Stratec Biomedical Q1 sales up at 49.5 mln euros

* Q1 sales rose 58.6 percent to 49.5 million euros ($53.93 million)

BRIEF-Stratec Biomedical FY consolidated net income up at EUR 25.4 mln

* FY sales rose 25.9 percent to 184.9 million euros ($198.32 million)

BRIEF-Stratec Biomedical hikes dividend after 2016 profit gain

* Dividend 0.77 eurper share versus 0.75 eurper share year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up